Drug General Information
Drug ID
D0G0WC
Former ID
DNC013392
Drug Name
2-(3-bromophenyl)-7-methyl-1,8-naphthyridine
Drug Type
Small molecular drug
Indication Discovery agent Investigative [529101]
Formula
C15H11BrN2
Canonical SMILES
CC1=NC2=C(C=C1)C=CC(=N2)C3=CC(=CC=C3)Br
InChI
1S/C15H11BrN2/c1-10-5-6-11-7-8-14(18-15(11)17-10)12-3-2-4-13(16)9-12/h2-9H,1H3
InChIKey
YAOUIVOXDAAEBA-UHFFFAOYSA-N
PubChem Compound ID
Target and Pathway
Target(s) Metabotropic glutamate receptor 5 Target Info Inhibitor [529101]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Long-term potentiation
Retrograde endocannabinoid signaling
Glutamatergic synapse
Huntington's disease
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Metabotropic glutamate receptor group III pathway
Metabotropic glutamate receptor group I pathway
Endogenous cannabinoid signaling
Reactome G alpha (q) signalling events
Class C/3 (Metabotropic glutamate/pheromone receptors)
WikiPathways Hypothetical Network for Drug Addiction
GPCRs, Class C Metabotropic glutamate, pheromone
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR ligand binding
GPCR downstream signaling
References
Ref 529101Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8. Epub 2007 Sep 29.Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists.
Ref 529101Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8. Epub 2007 Sep 29.Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists.